Ultragenyx Pharmaceutical Inc (RARE)

37.50 -1.40  -3.60% NASDAQ Nov 11, 20:00 Delayed 2m USD
View Full Chart
Price Chart
View All Events

Events

Date Type Description
02/19/2020 17:00 EST Misc Ultragenyx Pharmaceutical Inc Fourth Quarter Earnings Conference Call in 2019
02/19/2020 Earnings Ultragenyx Pharmaceutical Inc Fourth Quarter Earnings in 2019 Release
11/05/2019 17:00 EST Misc Ultragenyx Pharmaceutical Inc Third Quarter Earnings Conference Call for 2019
11/05/2019 Earnings Ultragenyx Pharmaceutical Inc Third Quarter Earnings in 2019 Release
08/01/2019 17:00 EDT Misc Ultragenyx Pharmaceutical Inc Second Quarter Earnings Conference Call in 2019
08/01/2019 Earnings Ultragenyx Pharmaceutical Inc Second Quarter Earnings in 2019 Release
06/11/2019 14:00 PDT Misc Ultragenyx Pharmaceutical Inc Annual General Meeting in 2018
05/06/2019 17:00 EDT Misc Ultragenyx Pharmaceutical Inc First Quarter Earnings Conference Call in 2019
05/06/2019 Earnings Ultragenyx Pharmaceutical Inc First Quarter Earnings in 2019 Release
02/20/2019 Misc Ultragenyx Pharmaceutical Inc Annual Report in 2018
View All Performance Charts

Total Returns Comparison

Ratings & Reports

Advertisement
Edit

Profile

  • URL: http://www.ultragenyx.com
  • Investor Relations URL: http://ir.ultragenyx.com/
  • HQ State/Province: California
  • Sector: Healthcare
  • Industry: Biotechnology
  • Equity Style: Small Cap/Growth
  • Next Earnings Release: Feb. 19, 2020
  • Last Earnings Release: Nov. 05, 2019
  • Next Ex-Dividend Date: N/A
  • Last Ex-Dividend Date: N/A
  • Description: Ultragenyx Pharmaceutical Inc is a US-based biopharmaceutical company. It identifies, acquires, develops, and commercialize novel products for the treatment of serious rare and ultra-rare diseases, with the focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.

Top Fund Holders

Symbol Name Weighting
GNOM Global X Genomics & Biotechnology ETF 2.54%
IMPAX ERShares US Small Cap Fund™ Inst 1.43%
KAUBX Federated Kaufmann B 1.31%
WSCAX Wanger International 1.15%
FKBSX Federated Kaufmann Small Cap B 0.99%

Comparables

Edit
Advertisement

{{root.upsell.info.feature_headline}}.

{{root.upsell.info.feature_description}}

Please note that this feature is only available as an add-on to YCharts subscriptions.


Please note that this feature requires full activation of your account and is not permitted during the free trial period.

Start My Free Trial {{root.upsell.info.call_to_action}} No credit card required.

Already a subscriber? Sign in.